227963-15-7
基本信息
L-000845704
HGFOOLONGOBCMP-IBGZPJMESA-N
3-Pyridinepropanoic acid, 6-methoxy-β-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-, (βS)-
物理化学性质
| 熔点 | 122 °C |
| 沸点 | 735.5±60.0 °C(Predicted) |
| 密度 | 1.36±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO : 250 mg/mL (568.82 mM) |
| 酸度系数(pKa) | 4.19±0.10(Predicted) |
| 形态 | Solid |
| 颜色 | White to off-white |
安全数据
| 危险性符号(GHS) |  GHS08 |
| 警示词 | 危险 |
| 危险性描述 | H373-H360 |
| 防范说明 | P260-P314-P501 |
常见问题列表
|
αvβ1 1.6 nM (IC 50 , inhibition of fibronectin-binding ) |
αvβ3 2.8 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ5 0.1 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ6 0.7 nM (IC 50 , inhibition of LAP-binding) |
αvβ8 0.5 nM (IC 50 , inhibition of LAP-binding) |
α5β1 12.2 nM (IC 50 , inhibition of fibronectin-binding) |
MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs.
| Animal Model: | B6D2F1 hybrid female mice |
| Dosage: | 100 or 300 mg/kg |
| Administration: | P.o., twice daily (b.i.d.), 2 weeks |
| Result: | MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle [2] . |